Biohaven enrolls first patient in phase 2/3 sinusitis trial of nurtec® odt

New haven, conn., feb. 22, 2022 /prnewswire/ -- biohaven pharmaceutical holding company ltd.

BHVN Ratings Summary

BHVN Quant Ranking